Recursion Pharmaceuticals (RXRX) closed at $3.61 on Oct 19, 2026, up 4.2% on the day. The stock is down 5.7% over the past month, up 17.2% over three months, down 11.7% year to date and down 43.2% over the past year. It trades 46.1% below its 52-week high of $6.70 and 30.3% above its 52-week low of $2.77. The close sits below its 50-day moving average ($3.63) and above its 200-day moving average ($3.56).
NextPick tracks RXRX in its AI Drug Discovery basket alongside TEM, ABCL, SDGR, CERT and ABSI. As of Oct 19, 2026, the basket's money-flow score is -38 (outflow), and the basket is down 6.9% over five sessions. Over the past month RXRX ranks 3rd of 6 basket members by price change.
Over its last 8 reports the stock moved an average of 4.7% on the first trading day after earnings, beating the options-implied move in 1 of 8.
Form 4 filings over the last 90 days show no open-market purchases and 5 open-market sales by insiders.
Over the last 8 reports, RXRX moved an average of 4.7% on the first trading day after earnings. The move beat the options-implied move in 1 of 8 reports.
Yes — the Oct 19, 2026 close of $3.61 is 1.4% above the 200-day average of $3.56.
RXRX closed 46.1% below its 52-week high of $6.70.
NextPick groups RXRX with TEM, ABCL, SDGR, CERT and ABSI in its AI Drug Discovery basket.
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. Its preclinical stage product includes REC-7735 for the treatment of HR+ breast cancer; and REC-102 for the treatment of hypophosphatasia. The company has collaboration and agreement with Roche & Genentech; Sanofi; Bayer AG; Tempus; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
